Molecular landscape of <scp><i>TP53</i></scp> mutations in breast cancer and their utility for predicting the response to <scp>HER</scp>‐targeted therapy in <scp>HER2</scp> amplification‐positive and <scp>HER2</scp> mutation‐positive amplification‐negative patients
Cancer medicine